Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-148771 NASTECH PHARMACEUTICAL COMPANY INC. Prospectus Supplement...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a Phase II clinical trial demonstrating that its...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter ended March 31, 2008...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial results will be released on...
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-148771 PROSPECTUS SUPPLEMENT (to Prospectus...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has entered into definitive agreements with new and...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.